Targeting HIF-1 for cancer therapy

Nature Reviews Cancer

Volumn 3, Issue 10, 2003, Pages 721-732

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1 METHYLPROPYL 2 IMIDAZOLYL DISULFIDE; 17 ALLYLAMINOGELDANAMYCIN; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELECOXIB; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLEUROTIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TISSUE OXYGENATION; TRANSCRIPTION REGULATION; TREATMENT FAILURE; TUMOR GROWTH; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASMS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 0142166332     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1187     Document Type: Review

References (107)

1. Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol. Cell. Biol. 12, 5447-5454 (1992).
2. Wang, G. L. & Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237 (1995).
3. 2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514 (1995).
4. Harris, A. L. Hypoxia - a key regulatory factor in tumor growth. Nature Rev. Cancer 2, 38-46 (2001).
5. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis. cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
6. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162 (1998).
7. Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015 (1998).
8. Krishnamachary, B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63, 1138-1143 (2003).
9. Wykoff, C. C. et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19, 6297-6305 (2000).
10. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
11. Yu, J. et al. Identification and classification of p53-regulated genes. Proc. Natl Acad. Sci. USA 96, 14517-14522 (1999).
12. Ema, M. et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development Proc. Natl Acad. Sci. USA 94, 4273-4278 (1997).
13. Flamme, I. et al. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels. Mech. Dev. 63, 51-60 (1997).
14. Hogenesch, J. B. et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway, J. Biol. Chem. 272, 8581-8593 (1997).
15. Tian. H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72-82 (1997).
16. Brusselmans, K. et al. Hypoxia-inducible factor-2α (HIF-2α) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J. Biol. Chem. 276, 39192-39196 (2001).
17. Makino, Y. et al. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of thehypoxia-inducible factor-3α locus J. Biol. Chem. 277, 32405-32408 (2002).
18. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
19. Epstein, A. C. et al. C elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
20. 2 sensing Science 292, 464-468 (2001).
21. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
22. Masson, N. et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation EMBO J. 20, 5197-5206 (2001).
23. Yu, F., White, S. B., Zhao, Q. & Lee, F. S. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation Proc. Natl Acad. Sci. USA 98, 9630-9635 (2001).
24. Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733-25741 (2000).
25. Kamura, T. et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430-10435 (2000).
26. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
27. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427 (2000).
28. Tanimoto, K., Makino, Y, Pereira, T. & Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor protein. EMBO J. 19, 4298-4309 (2000).
29. 2 tension. Am. J. Physiol. 271, C1172-C1180 (1996).
30. Jeong, J. W. et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709-720 (2002).
31. Jiang, B.-H. et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1α: modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272, 19253-19260 (1997).
32. Pugh, C. W. et al. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J Biol. Chem. 272, 11205-11214 (1997).
33. Mahon, P. C., Hirota. K. & Semenza, G. L. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686 (2001).
34. Hewitson, K. S. et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol. Chem. 277. 26351-26355 (2002).
35. Lando, D. et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861 (2002).
36. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002).
37. Dames, S. A. et al. Structural basis for HIF-1α/CBP recognition in the cellular hypoxic response. Proc. Natl Acad. Sci. USA 99, 5271-5276 (2002).
38. Freedman, S. J. et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α. Proc. Natl Acad. Sci. USA 99, 5367-5372 (2002)
39. Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975-978 (2002).
40. Min, J. H. et al. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling Science 296, 1886-1889 (2002).
41. Brand, K. A. & Hermfisse, U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 11, 388-395 (1997).
42. Seagroves, T. N. et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 21, 3436-3444 (2001).
43. Jiang, B. H., Agani, F. Passaniti, A. & Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HI F-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328-5335 (1997).
44. Fukuda, R. et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277, 38205-38211 (2002).
45. 2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63, 2330-2334 (2003).
46. Hellwig-Burgel, T., Stiehl, D. P. & Jelkmann, W. in Oxygen Sensing: Responses and Adaptation to Hypoxia (eds Lahiri, S., Semenza, G. L. & Prabhakar, N. R.) 95-108 (Marcel Dekker, Inc., New York, 2003).
47. Laughner, E. et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004 (2001).
48. Zhong, H. et al. Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics, Cancer Res. 60, 1541-1545 (2000).
49. Zundel, W. et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14. 391-396 (2000).
50. Richard, D. E. et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274, 32631-32637 (1999).
51. Sodhi, A. et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α. Cancer Res. 60, 4873-4880 (2000).
52. Sang, N. et al. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 278, 14013-14019 (2003).
53. Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of repamycin. Mol. Cell. Biol. 22, 7004-7014 (2002).
54. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59, 5830-5835 (1999).
55. Feldser, D. et al. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. 59, 3915-3918 (1999).
56. Talks, K. L. et al. The expression and distnbution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages Am. J. Pathol. 157, 411-421 (2000).
57. Beasley, N. J. et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62, 2493-2497 (2002).
58. Volm, M. & Koomagi, R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer Anticancer Res. 20, 1527-1533 (2000).
59. Giatromanolaki, A. et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890 (2001).
60. Koukourakis. M. I. et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 1192-1202 (2002).
61. Birner, P. et al. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7, 1661-1668 (2001).
62. Koukourakis, M. I. et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 61, 1830-1832 (2001).
63. Maxwell, P. H. et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 94, 8104-8109 (1997).
64. Ryan, H. E. et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015 (2000).
65. Unruh, A. et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy Oncogene 22, 3213-3220 (2003).
66. Ravi, R. et al Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44 (2000).
67. Akakura, N. et al. Constitutive expression of hypoxia-inducible factor 1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation Cancer Res. 61, 6548-6554 (2001).
68. Jiang, B. H. et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271, 17771-17778 (1996).
69. Chen, J. et al. Dominant-negative hypoxia-inducible factor 1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 162, 1283-1291 (2003).
70. Kung, A. L. et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Med. 6, 1335-1340 (2000).
71. Kondo, K. et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
72. Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF-1α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002)
73. Mack, F. A. et al. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3, 75-88 (2003).
74. Bernards, R. & Weinberg, R. A. Metastasis genes: a progression puzzle. Nature 418, 823 (2002).
75. An, W. G. et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392, 405-408 (1998).
76. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl Acad. Sci. USA 97, 9082-9087 (2000).
77. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
78. Bos, R. et al. Levels of hypoxia-inducible factor 1α during breast carcinogenesis. J. Natl Cancer Inst. 93, 309-314 (2001).
79. Semenza, G. L. Angiogenesis in ischemic and neoplastic disorders Annu. Rev. Med. 54, 17-28 (2003).
80. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266-276 (2001).
81. Aebersold, D. M. et al. Expression of hypoxia-inducible factor 1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61, 2911-2916 (2001).
82. Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316-4324 (2002).
83. Yeo, E. J. et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl Cancer Inst. 95, 516-525 (2003).
84. Isaacs, J. S. et al. Hsp90 regulates a von Hippel-Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
85. Mabjeesh, N. J. et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62, 2478-2482 (2002).
86. Zagzag, D. et al. Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1α) in glioma cell invasion. J. Cell. Physiol. 196, 394-402 (2003).
87. Welsh, S. J. et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol. Cancer Ther. 2, 235-243 (2003).
88. Mabjeesh, N. J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375 (2003).
89. Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002).
90. Zagzag, D. et al. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618 (2000).
91. Price, J. E., Polyzos, A, Zhang, R. D. & Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50, 717-721 (1990).
92. Holland, E. C. Gliomagenesis: genetic alterations and mouse models. Nature Rev. Genet. 2, 120-129 (2001).
93. Van Dyke, T. & Jacks, T. Cancer modeling in the modern era: progress and challenges. Cell 108, 135-144 (2002).
94. Romper M. G. Can small animal imaging accelerate drug development? J. Cell. Biochem. 39 (Suppl.), 211-220 (2002).
95. Artemov, D., Mori, N., Ravi, R. & Bhujwalla, Z. M. Magnetic resonance molecular imaging of the her-2/neu receptor. Cancer Res. 63, 2723-2727 (2003).
96. Bhujwalla, Z. M. et al. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res. 9, 355-362 (2003).
97. Mankoff, D. A. et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy J. Nucl. Med. 43, 500-509 (2002).
98. 2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a human prostate cancer cell line J. Biol. Chem. 277, 50081-50086 (2002).
99. ARF tumor suppressor protein facilitates nucleolar sequestration of HIF-1α and inhibits HIF-1 mediated transcription. J. Biol. Chem. 276, 28421-28429 (2001).
100. Iervolino, A. et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J. 16, 1453-1455.
101. Birner, P. et al. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60, 4693-4696 (2000).
102. Burri, P. et al. Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56, 494-501 (2003).
103. Schindl, M. et al. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8, 1831-1837 (2002).
104. Bos, R. et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97, 1573-1581 (2003).
105. Birner, P. et al. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoanglogenesis. Cancer 92, 165-171 (2001).
106. Sivridis, E, et al. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95, 1055-1063 (2002).
107. Takahashi, R. et al. Hypoxia-inducible factor-1α expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 10, 797402 797-802 (2003),.